Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [33]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citation(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032
Research works printed but not linked: 8
- Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
- Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
- Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
- Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
- Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
- Lukas, J. et al. Oncogene (in the press).
Cited by
Items 301–400 of 902
Signaling by ABL oncogenes through cyclin D1.
Afar, D. E., McLaughlin, J., Sherr, C. J., Witte, O. N., & Roussel, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9540 · Cited by 78
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Griewank, K., Scolyer, R. A., Thompson, J. F., Flaherty, K. T., Schadendorf, D., & Murali, R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt435 · Cited by 87
Havelek, R., Seifrtová, M., Královec, K., Brůčková, L., Cahlíková, L., Dalecká, M., Vávrová, J., Řezáčová, M., Opletal, L., & Bílková, Z. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.09.005 · Cited by 80
Developmental defects and tumor predisposition in Rb mutant mice
Vooijs, M., & Berns, A. J. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202999 · Cited by 82
“Overexpression of p16 induces a growth arrest in cells that have a functional pRB but not in cells lacking RB, suggesting they act in a linear pathway (Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995).”
BackgroundRodríguez‐Puebla, M. L., de Marval, P. L. M., LaCava, M., Moons, D. S., Kiyokawa, H., & Conti, C. J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64196-x · Cited by 86
Ruas, M., Brookes, S., McDonald, N. Q., & Peters, G. G. (1999) · Oncogene · doi:10.1038/sj.onc.1202918 · Cited by 81
“…have been described that use two types of readout: the ability of p16INK4a to cause a G1 cell cycle arrest in transfected cells (Koh et al., 1995; Lukas et al., 1995; Shapiro et al., 1995; Parry and Peters, 1996; Arap et al., 1997) and the interaction of p16INK4a with either endogenous or…”
BackgroundMethodResultInfluentialSelf-citationE2F-1 but not E2F-4 can overcome p16-induced G1 cell-cycle arrest
Mann, D. J., & Jones, N. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00515-8 · Cited by 95
Self-citationDefining a role for sphingosine kinase 1 in p53-dependent tumors
Heffernan-Stroud, L. A., Helke, K. L., Jenkins, R. W., Costa, A.-M. D., Hannun, Y. A., & Obeid, L. M. (2011) · Oncogene · doi:10.1038/onc.2011.302 · Cited by 81
“In contrast, evaluation of expression of p16 and p21, regulators of cell cycle arrest and senescence (el-Deiry et al., 1994; Lukas et al., 1995; Alesse et al., 1998; Bringold and Serrano, 2000) revealed differential expression of p21 and p16 in the thymi of the various genotypes (Figure 4c).”
Greussing, R., Hackl, M., Charoentong, P., Pauck, A., Monteforte, R., Cavinato, M., Hofer, E., Scheideler, M., Neuhaus, M., Micutkova, L., et al. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-224 · Cited by 70
“thereby enforcing prolonged cell cycle arrest [3], which”
BackgroundCurrent status of gene therapy for lung cancer and head and neck cancer.
Moon, C., Oh, Y. W., & Roth, J. A. (2003) · PubMed · Cited by 79
Müller-Decker, K., Kopp-Schneider, A., Marks, F., Seibert, K., & Fürstenberger, G. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199809)23:1<36::aid-mc5>3.0.co;2-f · Cited by 109
Progress in cancer genetics: Lessons from pancreatic cancer
Goggins, M., Kern, S. E., Offerhaus, J. A., & Hruban, R. H. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s4 · Cited by 70
“p 16 is a cyclin-dependent kinase inhibitor that prevents the cooperative action of the cyclin-dependent kinase CDK4 and cyclin Dl from phosphorylating Rb, an activity closely linked to the moving of the cell cycle out of late Gl phase [ 18 , 19].”
BackgroundToh, Y., Oki, E., Oda, S., Tokunaga, E., Ohno, S., Maehara, Y., Nicolson, G. L., & Sugimachi, K. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970822)74:4<459::aid-ijc18>3.0.co;2-4 · Cited by 165
Bockstaele, L., Coulonval, K., Kooken, H., Paternot, S., & Roger, P. P. (2006) · Cell Division · doi:10.1186/1747-1028-1-25 · Cited by 86
“Other CDK4/6 binding proteins including INK4 proteins [34,107] and Cdc37 [113] are mostly cytoplasmic proteins.”
BackgroundKnudsen, K. E., Fribourg, A. F., Strobeck, M. W., Blanchard, J.-M., & Knudsen, E. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27632 · Cited by 73
Nasu, K., Kohsaka, H., Nonomura, Y., Terada, Y., Ito, H., Hirokawa, K., & Miyasaka, N. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7246 · Cited by 75
Functional loss of E-cadherin and cadherin-11 alleles on chromosome 16q22 in colonic cancer
Braungart, E., Schumacher, C., Hartmann, E., Nekarda, H., Becker, K., H�fler, H., & Atkinson, M. J. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199904)187:5<535::aid-path302>3.0.co;2-g · Cited by 23
Lukas, J., Sørensen, C. S., Lukas, C., Santoni‐Rugiu, E., & Bártek, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202777 · Cited by 79
“Plasmids pBABE puro, pCMV-CD20 and the pGL3-TATA-6xE2F reporter were described (Lukas et al., 1996, 1997). p16 cDNA was excised from pXp16 (Lukas et al., 1995a) using BamHI and HindIII, blunt-ended and cloned into EcoRV site of the Figure 4 E ects of long-term induction of pRbDcdk (left panels) and…”
BackgroundMethodSelf-citationCancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity
Lilischkis, R., Šarčević, B., Kennedy, C. J., Warlters, A., & Sutherland, R. L. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960410)66:2<249::aid-ijc19>3.0.co;2-7 · Cited by 81
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma
Sandberg, A. A. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.11.009 · Cited by 78
Heinen, C. D., Goss, K. H., Cornelius, J. R., Babcock, G. F., Knudsen, E. S., Kowalik, T. F., & Groden, J. L. (2002) · Gastroenterology · doi:10.1053/gast.2002.35382 · Cited by 81
Gabrielli, B. G., Šarčević, B., Sinnamon, J., Walker, G. J., Castellano, M., Wang, X., & Ellem, K. A. O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13961 · Cited by 79
Smad3 phosphorylation by cyclin-dependent kinases
LIU, F. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.010 · Cited by 71
Yang, P., Ma, J., Zhang, B., Duan, H., He, Z., Zeng, J.-L., Zeng, X., Li, D., Wang, Q., Xiao, Y., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0784 · Cited by 79
“Suppression of its expression allows unregulated phosphorylation of the Rb protein and leads to uncontrolled cell-cycle progression and cell division (15).”
BackgroundAusoni, S., Boscolo‐Rizzo, P., Singh, B., Mosto, M. C. D., Spinato, G., Tirelli, G., Spinato, R., & Azzarello, G. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9625-1 · Cited by 73
TAP1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis
Kamarashev, J. A., Ferrone, S., Seifert, B., B�ni, R., Nestle, F. O., Burg, G., & Dummer, R. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010120)95:1<73::aid-ijc1013>3.0.co;2-s · Cited by 79
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10<2099::aid-cncr8>3.0.co;2-3 · Cited by 2,101
Chen, T.-T., & Wang, J. Y. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5571-5580.2000 · Cited by 71
“The second is based on Rb-deficient mouse embryo fibroblasts, which become G1-arrested upon the coexpression of RB and p16Ink4a to inhibit RB phosphorylation (13, 28, 32).”
BackgroundCamarda, G., Siepi, F., Pajalunga, D., Bernardini, C., Rossi, R., Montecucco, A., Meccia, E., & Crescenzi, M. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408164 · Cited by 69
Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R. T., Patil, D. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0574-9 · Cited by 73
El‐Naggar, A. K., Lai, S., Clayman, G. L., Zhou, J.-H., Tucker, S., Myers, J., Luna, M. A., & Benedict, W. F. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90217-4 · Cited by 69
Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect
Auroy, S., Avril, M., Chompret, A., Pham, D., Goldstein, A. M., Bianchi‐Scarrà, G., Frébourg, T., Joly, P., Spatz, A., Rubino, C., et al. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1183 · Cited by 72
Kubo, A., Nakagawa, K., Varma, R. K., Conrad, N. K., Cheng, J. Q., Lee, W. C., Testa, J. R., Johnson, B. E., Kaye, F. J., & Kelley, M. J. (1999) · PubMed · Cited by 81
Swope, V., Alexander, C., Starner, R., Schwemberger, S., Babcock, G., & Abdel‐Malek, Z. A. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12252 · Cited by 67
“The p16 gene codes for a cyclin D1/cdk4 inhibitor that prevents the progression of cells from G1 to S phase of the cell cycle and reduces oxidative stress in melanocytes (Jenkins et al., 2011; Lukas et al., 1995).”
BackgroundSasaki, M., Kajiya, H., Ozeki, S., Okabe, K., & Ikebe, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.123 · Cited by 67
Mechanisms that mediate stem cell self‐renewal and differentiation
Zhang, H., & Wang, Z. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21460 · Cited by 78
“, 1994, 1996], which are common features of cancer cells [Lukas et al., 1995; Medema et al., 1995].”
BackgroundEffects of androgens on telomerase activity in normal and malignant prostate cells in vitro
Soda, H., Raymond, É., Sharma, S., Lawrence, R. A., Davidson, K. K., Oka, M., Kohno, S., Izbicka, E., & Hoff, D. D. V. (2000) · The Prostate · doi:10.1002/(sici)1097-0045(20000515)43:3<161::aid-pros1>3.0.co;2-o · Cited by 54
Knudsen, K. E., Weber, E., Arden, K. C., Cavenee, W. K., Feramisco, J. R., & Knudsen, E. S. (1999) · Oncogene · doi:10.1038/sj.onc.1202910 · Cited by 79
“In contrast PSM-RB was a very potent inhibitor of cell cycle progression, inhibiting the incorporation of BrdU by a 3 ± 11-fold dependent on cell line, similar to the action of p16ink4a which is known to arrest tumor cell lines expressing functional endogenous RB (Lukas et al., 1995) (Figure 1a).”
BackgroundNiehans, G. A., Kratzke, R. A., Froberg, M. K., Aeppli, D. M., Nguyen, P. L., & Geradts, J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6990483 · Cited by 67
“…GST-p16INK4a protein and a neutralizing antibody to cyclin D1 synergistically enhanced arrest, leading them to hypothesize that in Rb-competent cells the balance between functional cyclin D1 and p16INK4a which determines whether or not cells will proceed through the checkpoint (Lukas et al, 1995a).”
BackgroundCDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults—An array CGH study
Usvasalo, A., Savola, S. P., Räty, R., Vettenranta, K. K., Harila‐Saari, A. H., Koistinen, P., Savolainen, E., Elonen, E., Saarinen‐Pihkala, U. M., & Knuutila, S. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.01.014 · Cited by 66
Evans, R., Wyllie, F. S., Wynford‐Thomas, D., Kipling, D., & Jones, C. J. (2003) · PubMed · Cited by 82
Nilsson, K., & Landberg, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.21466 · Cited by 73
Genetic Replacement of Cyclin D1 Function in Mouse Development by Cyclin D2
Carthon, B. C., Neumann, C. A., Das, M., Pawlyk, B. S., Li, T., Geng, Y., & Siciński, P. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.3.1081-1088.2005 · Cited by 72
“The phosphorylation of these pocket proteins may represent the major function for cyclin D-CDK complexes in cell cycle progression, as shown by the observations that cells lacking pRB or p107 and p130 no longer require D cyclins for proliferation (1, 4, 16, 23, 29 , 35, 40, 53).”
BackgroundThrombospondin-1 Is a Transcriptional Repression Target of PRMT6
Michaud‐Levesque, J., & Richard, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.005322 · Cited by 64
Depoortere, F., Keymeulen, A. V., Lukas, J., Costagliola, S., Bártková, J., Dumont, J. E., Bártek, J., Roger, P. P., & Dremier, S. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.6.1427 · Cited by 66
“…and growth factor mitogenic pathways, since the microinjection of the p16INK4A inhibitor of cdk4 blocked the stimulation of DNA synthesis by TSH and EGF in dog thyrocytes (Lukas et al., 1996b), exactly as in growth factor–stimulated fibroblasts with a normal Rb function (Lukas et al., 1995c).”
InfluentialSelf-citationSever-Chroneos, Z., Angus, S. P., Fribourg, A. F., Wan, H., Todorov, I., Knudsen, K. E., & Knudsen, E. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4032-4045.2001 · Cited by 64
“RB is the critical substrate for cyclin D-associated kinase activity, as cyclin D and CDK4 are not required in the absence of functional RB (38, 40 ).”
BackgroundWang, L., Liu, R., Ye, P., Wong, C.-S., Chen, G., Zhou, P., Sakabe, K., Zheng, X., Wu, W., Zhang, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms6909 · Cited by 66
Protein dephosphorylation and the intracellular control of the cell number
Berndt, N. (1999) · Frontiers in bioscience · doi:10.2741/berndt · Cited by 70
“blocking the initial RB phosphorylation (99).”
BackgroundLoignon, M., Fetni, R., Gordon, A. J., & Drobetsky, E. A. (1997) · PubMed · Cited by 75
Hua, D., Hu, Y., Wu, Y.-Y., Cheng, Z.-H., Yu, J., Du, X., & Huang, Z. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.05.001 · Cited by 62
Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner
Aoki, S., Kong, D., Suna, H., Sowa, Y., Sakai, T., Setiawan, A., & Kobayashi, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.119 · Cited by 62
Damia, G., Imperatori, L., Stefanini, M., & D'Incalci, M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960611)66:6<779::aid-ijc12>3.0.co;2-z · Cited by 132
Self-citationImplication of transcription factor E2F in regulation of DNA replication
Ohtani, K. (1999) · Frontiers in bioscience · doi:10.2741/a396 · Cited by 67
Yang, X., Jin, G., Nakao, Y., Rahimtula, M., Pater, M. M., & Pater, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960126)65:3<275::aid-ijc1>3.0.co;2-x · Cited by 50
Adamsen, B. L., Kravik, K., Clausen, O. P. F., & Angelis, P. D. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.6.1491 · Cited by 64
Schnier, J. B., Nishi, K., Goodrich, D. W., & Bradbury, E. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5941 · Cited by 62
Thullberg, M., Bártek, J., & Lukas, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203579 · Cited by 64
“Consequently, overexpression of several INK4 proteins arrests the cells in G1 phase, in a strictly pRb-dependent manner (Guan et al., 1994; Medema et al., 1995; Koh et al., 1995; Lukas et al., 1995c).”
BackgroundMethodSelf-citation浜田, 邦., Kohno, T., Kawanishi, M., Ohwada, S., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199807)22:3<232::aid-gcc9>3.0.co;2-x · Cited by 67
Hypermethylation in bladder cancer: biological pathways and translational applications
Sänchez‐Carbayo, M. (2012) · Tumor Biology · doi:10.1007/s13277-011-0310-2 · Cited by 62
Deregulation of the G1/S‐phase control in human testicular germ cell tumours
Bártková, J., Meyts, E. R., Skakkebæk, N. E., LUKAS, J., & Bártek, J. (2003) · Apmis · doi:10.1034/j.1600-0463.2003.1110129.x · Cited by 66
Self-citationAusserlechner, M. J., Obexer, P., de Bock, G. H., Geley, S., & Kofler, R. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401328 · Cited by 65
Cancer takes many paths through G1/S
Knudsen, E. S., Witkiewicz, A. K., & Rubin, S. M. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.10.007 · Cited by 63
Schraml, P., Struckmann, K., Bednar, R., Fu, W., Gasser, T., Wilber, K., Kononen, J., Sauter, G., Mihatsch, M. J., & Moch, H. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64001-1 · Cited by 58
Cellular signaling in normal and cancerous stem cells
Grinstein, E., & Wernet, P. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.06.021 · Cited by 61
Hlobílková, A., Guldberg, P., Thullberg, M., Zeuthen, J., Lukas, J., & Bártek, J. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4867 · Cited by 64
Self-citationThe Rb pathway in neurogenesis
Ferguson, K. L., & Slack, R. S. (2001) · Neuroreport · doi:10.1097/00001756-200107030-00001 · Cited by 57
Human papillomavirus in esophageal squamous cell carcinoma in Colombia and Chile
Castillo, A. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i38.6188 · Cited by 57
“D1 and cyclin-dependent kinase 4 and represses its ability to phosphorylate the retinoblastoma protein (pRb) [13, 14 ]”
BackgroundThe Physiology of p16INK4A-Mediated G1 Proliferative Arrest
Shapiro, G. I., Edwards, C. D., & Rollins, B. J. (2000) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:33:2:189 · Cited by 63
Ceruti, J. M., Scassa, M. É., Fló, J., Varone, C. L., & Cánepa, E. T. (2005) · Oncogene · doi:10.1038/sj.onc.1208570 · Cited by 59
“Several authors have demonstrated that overexpressed INK4 proteins arrest the cell cycle in G1 phase in a manner that depends on Rb integrity (Lukas et al., 1995; Guan et al., 1996; Sherr and Roberts, 1999).”
BackgroundGeradts, J., Hruban, R. H., Schutte, M., Kern, S. E., & Maynard, R. (2000) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/00129039-200003000-00011 · Cited by 56
The therapeutic potential of targeting the cell cycle
Webster, K. R. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.6.865 · Cited by 60
Malignant Progression in Barrett’s Esophagus: Pathology and Molecular Biology
Mueller, J. D., Werner, M., & Siewert, J. R. (2000) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-59600-1_3 · Cited by 56
Expression of p16INK4A and p14ARF in hematological malignancies
Taniguchi, T., Chikatsu, N., Takahashi, S., Fujita, A., Uchimaru, K., Asano, S., Fujita, T., & Motokura, T. (1999) · Leukemia · doi:10.1038/sj.leu.2401557 · Cited by 57
Mechanisms of TGF-β-Induced Cell Cycle Arrest
Hocevar, B. A., & Howe, P. H. (1998) · Mineral and Electrolyte Metabolism · doi:10.1159/000057360 · Cited by 62
Reddy, K. B., Krueger, J. S., B. Kondapaka, S., & Diglio, C. A. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990719)82:2<268::aid-ijc18>3.0.co;2-4 · Cited by 149
Mishina, T., Dosaka‐Akita, H., Kinoshita, I., Hommura, F., Morikawa, T., Katoh, H., & Kawakami, Y. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690500 · Cited by 55
Key Effectors of Signal Transduction and G 1 Progression
Roussel, M. F. (1998) · Advances in cancer research · doi:10.1016/s0065-230x(08)60763-0 · Cited by 72
Becker, T. M., Rizos, H., Kefford, R. F., & Mann, G. J. (2001) · PubMed · Cited by 54
Lewis, J. L., Chinswangwatanakul, W., Zheng, B., Marley, S. B., Nguyen, D. X., Cross, N. C. P., Banerji, L., Glassford, J., Thomas, N. S. B., Goldman, J. M., et al. (2001) · Blood · doi:10.1182/blood.v97.9.2604 · Cited by 53
Bartkova, J., Rajpert‐De Meyts, E., Skakkebæk, N. E., Lukas, J., & Bartek, J. (2007) · International Journal of Andrology · doi:10.1111/j.1365-2605.2007.00772.x · Cited by 53
Comparative structure and characterization of a CDKN2 gene in a Xiphophorus fish melanoma model
Kazianis, S., Morizot, D. C., Coletta, L. D., Johnston, D., Woolcock, B. W., Vielkind, J., & Nairn, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202884 · Cited by 57
“…established, for example, that while human p15CDKN2B and p16CDKN2A both bind to CDK4/CDK6, they are expressed di erently in various tissues, and their respective promoters are divergent in sequence and responsiveness to TGFb and pRB levels (Hara et al., 1996; Li et al., 1995; Lukas et al., 1995).”
BackgroundGonzalez‐Quevedo, R., Iniesta, P., Morán, A., de Juan, C., Sánchez-Pernaute, A., Fernández, C., Torres, A., Díaz-Rubio, E., Balibrea, J.-L., & Benito, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.254 · Cited by 55
Alevizopoulos, K., Catarin, B., Vlach, J., & Amati, B. B. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5987 · Cited by 58
“For example, pRb-negative cells become insensitive to expression of p16 or microinjection of antibodies neutralizing cyclin D/CDK4 (Lukas et al., 1994, 1995a, 1995b; Koh et al., 1995; Medema et al., 1995) and ectopic expression of E2F/DP proteins prevents G1 block by p16, allowing cells to enter S phase (DeGregori et…”
BackgroundCancer cell cycle dystopia: heterogeneity, plasticity, and therapy
Witkiewicz, A. K., Kumarasamy, V. M., Sanidas, I., & Knudsen, E. S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.006 · Cited by 56
Induction of Cell Activation Processes by Low Frequency Electromagnetic Fields
Simkó, M. (2004) · The Scientific World JOURNAL · doi:10.1100/tsw.2004.174 · Cited by 56
Joyce, N. C., & Harris, D. L. (2010) · PubMed Central · Cited by 51
Unmasking the Lung Cancer Epigenome
Belinsky, S. A. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-072018 · Cited by 54
Differential expression of cyclin D1, Ki‑67, pRb, and p53 in psoriatic skin lesions and normal skin
Kim, S. O., Ryu, Y., Kwon, J., Choe, M. S., Jung, J. M., & Choi, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8015 · Cited by 51
“The phosphorylation status of pRb is specifically regulated by the activities of cyclin D1, cyclin E, and p16 (21,22).”
Santos, L. L., Amaro, T., Pereira, S., Lameiras, C., Lopes, P., Bento, M. J., Oliveira, J., Criado, M. B., & Lopes, C. (2003) · European Journal of Surgical Oncology · doi:10.1053/ejso.2002.1371 · Cited by 51
Ravi, R. K., Thiagalingam, A., Weber, E., McMahon, M., Nelkin, B. D., & Mabry, M. H. (1999) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.20.4.3406 · Cited by 51
“cdk2 (29). In Rb-positive cells, cell cycle inhibitors of the INK class, such as p16INK4, can induce cell cycle arrest, by inhibiting cdk4 and cdk6 activity, which are necessary to phosphorylate Rb prior to entry into the S phase ( 30 , 31).”
BackgroundAnalysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma
Tasaka, T., Berenson, J. R., Vescio, R. A., Hirama, T., Miller, C. W., Nagai, M., Takahara, J., & Koeffler, H. P. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.8552482.x · Cited by 51
“Furthermore, we were unable to detect any point mutations of the p15 and p16 genes in our ALL, ATL, NHL and acute and chronic myeloid leukaemia series (Hatta et al, 1995; Nakamaki et al, 1995; Takeuchi et al, 1995).”
BackgroundDifferential retinoblastoma and p16INK4A protein expression in neuroendocrine tumors of the lung
Dosaka‐Akita, H., Cagle, P. T., Hiroumi, H., Fujita, M., Yamashita, M., Sharma, A., Kawakami, Y., & Benedict, W. F. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000201)88:3<550::aid-cncr9>3.0.co;2-d · Cited by 53
“p16 (p16) protein, the product of the CDKN2 gene, which has been found to be deleted in a variety of tumor cells,(29,30) inhibits CDK4- and CDK6-mediated phosphorylation of RB protein.(31,32) Therefore, p16 and RB proteins are suggested to function in a single regulatory pathway of the cell cycle and tumor suppression…”
BackgroundAdachi, M., Roussel, M. F., Havenith, K., & Sherr, C. J. (1997) · Blood · doi:10.1182/blood.v90.1.126 · Cited by 51
Lou, X., Zhang, J., Liu, S., Lou, X., & Liao, D. J. (2014) · Cell Cycle · doi:10.4161/cc.29082 · Cited by 51
Cyclin-Dependent Kinase Inhibitors and Human Cancer
Kamb, A. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_7 · Cited by 57
Frost, S. J., Simpson, D. J. W., Clayton, R. N., & Farrell, W. E. (1999) · Molecular Endocrinology · doi:10.1210/me.13.11.1801 · Cited by 52
The urokinase-type plasminogen activator system in cancer metastasis: A review
Andreasen, P. A., Kjøller, L., Christensen, L., & Duffy, M. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970703)72:1<119::aid-ijc17>3.0.co;2-e · Cited by 1,552
Epigenetics of lung cancer: a translational perspective
Quintanal-Villalonga, À., & Molina‐Pinelo, S. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00465-9 · Cited by 54
p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma
Platt, G., Carbone, A., & Mittnacht, S. (2002) · Oncogene · doi:10.1038/sj.onc.1205360 · Cited by 49
“The ability of the p16INK4a protein to promote G1 phase cell cycle arrest absolutely depends upon the presence of functional Rb (Lukas et al., 1995; Medema et al., 1995) and Rb phosphorylation by cdk4 and cdk6 kinases is rate limiting for cell cycle progression.”
BackgroundBiologic and Biochemical Analyses of p16INK4a Mutations From Primary Tumors
Yarbrough, W. G., Buckmire, R. A., Bessho, M., & Liu, E. T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1569 · Cited by 49
Metadata
- Authors
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- ORCID
- Mann, David J.
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2010493387
- Cited by
- 899
- References
- 28
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 22 · 2012: 16
- FWCI
- 32.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, retinoblastoma protein, CDKN2, tumour suppressor, cell cycle arrest, G1 phase progression, D-type cyclins, CDK4, CDK6, retinoblastoma, carcinogenesis, chromosome 9p21
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Cells, Cultured, Cloning, Molecular, Escherichia coli, Humans, Mice, Inbred BALB C, Microinjections, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Tumor Cells, Cultured, Oncogene Proteins, Genes, Tumor Suppressor, Retinoblastoma Protein, G1 Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.